Skip to main content
Premium Trial:

Request an Annual Quote

Icoria Books Record Revenues from Contracts, Though Net Loss Swells 40 Percent

NEW YORK, Nov. 8 (GenomeWeb News) - Icoria today reported record revenues from contract work for the third quarter of 2004, while its loss increased.

 

The company booked $7.1 million in revenues for the quarter ended Sept. 30, up from $6 million during last year's third quarter. The revenue, the highest the company ever received during a quarter, were due primarily to revenues from existing contracts from the NIEHS and Pioneer. Icoria also said it has signed new contracts with pharmaceutical companies that will contribute to revenues during the next quarter.

 

Icoria's R&D expenses climbed to $7.5 million from $6.2 million during the same quarter a year ago.

 

The company's net loss for the quarter swelled by 40 percent to $3.1 million, or $.08 per share, from $2.2 million, or $.07 per share, during the year-ago period. This increase derived from higher material costs for contract work, increased R&D costs, additional sales and marketing costs, and amortization of assets associated with the acquisition of TissueInformatics.

 

As of Sept. 30, Icoria, formerly Paradigm Genetics, had $7.1 million in cash, cash equivalents, and short-term investments.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.